US FDA's New Paragraph IV Data Further Illustrates Generic Competition Problems

 
• By Derrick Gingery

Data on the number of ANDAs submitted with valid paragraph IV certifications shows some products with strong generic interest and others with almost none.

Generics
The US FDA is releasing more patent-related information for generic drug sponsors. • Source: Shutterstock

More from Generics

More from Biosimilars & Generics